PCVX Vaxcyte, Inc.
FY2025 10-K
Vaxcyte, Inc. (PCVX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 24, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development and commercialization of proprietary pneumococcal conjugate vaccines
- • New manufacturing agreement with Lonza Ltd effective January 2026 for development and commercial supply of vaccine components
Management Discussion & Analysis
- • No revenue generated in FY 2026 as Vaxcyte is clinical-stage; net losses $766.6M in 2025 vs $463.9M in 2024 vs $402.3M in 2023
- • Operating losses increased due to advancing clinical trials and manufacturing scale-up; cash, equivalents, investments $2.44B as of Dec 31, 2025
Risk Factors
- • Cybersecurity breach risk with potential regulatory fines, investigations, operational disruptions, and reputational harm
- • SVP IT with 30+ years experience leads cybersecurity risk management and incident response
Financial SummaryXBRL
Net Income
-$767M
ROE
-28.5%
Total Assets
$3.0B
EPS (Diluted)
$-5.63
Operating Cash Flow
-$656M
Source: XBRL data from Vaxcyte, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Vaxcyte, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.